



Advances in Vaccine Adjuvant/Delivery System

Guest Editor:

Dr. Ting Wang

School of Pharmacy, Anhui
Medical University, Hefei 230000,
China

Deadline for manuscript
submissions:

closed (15 January 2023)

Message from the Guest Editor

Dear Colleagues,

Vaccine adjuvant/immunomodulator and delivery systems (VADSs), either directly or indirectly, have become integral components of many vaccines. At present, a variety of vaccines, based on RNA, DNA, recombinant proteins, inactivated and attenuated viruses, or viral vectors, are being tested with a variety of VADSs. Although the exact mechanism of action of many adjuvants and VADSs remains unknown, they provide a lasting immune memory and enhanced efficacy of vaccines by modulating innate and adaptive immune responses and promoting immune responses to antigens. The purpose of this Special Issue is to present the latest developments in vaccine adjuvant and delivery systems (VADSs).

We invite potential researchers to submit an article, review, etc., on the mechanisms and actions of vaccine adjuvants and VADSs and their recent developments. Priority will be given to articles that focus on newly emerging or highly dangerous infectious agents in humans or animals (e.g., coronavirus, influenza, hepatitis, dengue, malaria, HIV, RSV, etc.).

I look forward to receiving your contributions.

Dr. Ting Wang
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)